Is dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer feasible because of excessive diarrhea?
Dose-dense AC followed by PTL and then followed by TL was not feasible because of a high rate of lapatinib dose reduction, mostly caused by unacceptable grade 3 diarrhea. Lapatinib (1,000 mg/d) was not feasible combined with weekly PT.
These findings suggest that climacterium is included, at least in part, in the risk factors for contrast-induced adverse pulmonary reactions, and this risk is lowered by estrogen replacement therapy.